Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis

Cancer Research and Treatment

Volumn 48, Issue 2, 2016, Pages 843-847

  Park, Won Young ^a   Kim, Han Jo ^b   Kim, Kyoungha ^a   Bae, Sang Byung ^b   Lee, Namsu ^a   Lee, Kyu Taek ^b   Won, Jong Ho ^a   Park, Hee Sook ^a   Lee, Sang Cheol ^b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Intrathecal injection; Leptomeningeal carcinomatosis; Trastuzumab

Indexed keywords

ANASTROZOLE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; GOSERELIN; LAPATINIB; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CARCINOMATOUS MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAIT DISORDER; HUMAN; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; BREAST TUMOR; COMPLICATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BREAST NEOPLASMS; FEMALE; HUMANS; MENINGEAL CARCINOMATOSIS; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECEPTOR, ERBB-2; SURVIVAL RATE; TRASTUZUMAB;

EID: 84963814092     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.234     Document Type: Article

References (11)

1. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103-19
2. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol. 1996;7:773-86
3. Pienkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol. 2010;21:917-24
4. Zagouri F, Sergentanis TN, Bartsch R, BerghoffAS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139:13-22
5. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010; 74:1449-54
6. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuz-umab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11 Suppl 1:4-12
7. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349-51
8. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18:23-8
9. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4(Suppl 4):S265-88
10. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. Highdose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19:1978-80
11. Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. Intrathecal trastuzumab: dose matters. Acta Oncol. 2012;51: 955-6